- Supplements Facts
- Scientific References
- Client Reviews
Protect Against Mental Decline with Stabilized TruePS™!
Phosphatidylserine (PS) is one of the body’s essential building blocks. It’s naturally found in the cell membrane and particularly abundant in the brain. In general, the human brain is very rich in lipid (fat) content. And PS accounts for 18% of all phospholipids in the brain – indicating its importance to normal cognitive function.
PS is crucial to the structure and function of nerve cells and plays a key role in cell-to-cell communication, information transfer, signaling and more.
The daily intake of PS is reduced in modern diets – largely due to a greater focus on lower fat foods. For example, it’s estimated that the average individual consumed 250mg of PS daily from food prior to the 1980s. Today the average person gets only about 130mg of PS daily from food (and a vegetarian diet provides only about 50mg/day).
Clinical studies demonstrate beneficial effects for supplementing our daily diet with 100mg to 300mg per day of PS (each TruePS™ soft gel provides 100mg of stabilized soy-free Sharp PS®).
PS benefits haven been demonstrated in over 30 clinical studies addressing the entire human life cycle – from children to adults to seniors. Here’s a summary of the PS findings:
- May help slow age-related mental decline, improving memory, attention and concentration.
- Helps improve mood and symptoms of anxiety and stress.
- May reduce risk of cognitive dysfunction and decrease loss of brain cells.
These benefits are possible only if you’re using a “stabilized” PS supplement. Unfortunately, PS is highly unstable and prone to degradation (and taking degraded PS won’t help you). In fact, a recent study showed a standard PS product degraded by 20% within 4.5 months of encapsulation.
TruePS™ overcomes this concern by using a clinically studied stabilization process. Shelf life studies have shown that even after 24 months, the PS showed absolutely no degradation. It was as potent at month 24 as it was the day the soft gel was made.
The Importance of Choosing a “Stabilized” Phosphatidylserine (PS) Supplement
Phosphatidylserine (PS) is a phospholipid that is a major component of cell membranes, making it a highly valuable nutrient for enhancing cognitive function. Without sufficient levels of PS, brain cells do not transmit nerve impulses properly.
TruePS™ is made with soy-free Sharp PS® - a high purity phosphatidylserine (PS) brand, developed and produced in Israel by Enzymotec Ltd. under the highest quality and safety standards.
In clinical testing, Sharp PS® has been shown to have a positive effect on memory recognition, memory recall, executive functions and mental flexibility.
Even though Sharp PS® is a very high quality PS, it like other phosphatidylserine is highly unstable and prone to degradation over time.
In fact, a recent shelf-life study, performed on a standard fluid PS material by an independent international laboratory for phospholipid analysis, showed dismaying results. Within 12 weeks of encapsulation, the standard fluid PS material had degraded by 10%. Within 18 weeks, it had degraded by nearly 20%.
As you might expect, when PS degrades, it is of little value to your brain cells.
To overcome the issue of PS stability, Soft Gel Technologies® has developed a method to enhance Sharp PS® using an exclusive fluid dispersion (provided as finished dosage soft gels) that has enviable stability.
Shelf-life studies on this stabilized Sharp PS®, performed by the same independent laboratory mentioned above, found that even after 24 months, the material showed absolutely no degradation. It was as potent at month 24 as it was the day it was encapsulated.
This allows you to use every bottle of TruePS™ with confidence, knowing that the PS is active and able to provide maximum benefits.
Dietary Supplement / 30 Softgels
Serving Size: 1 Softgel
Servings per Container: 30
|Amount Per Serving||% Daily Value|
|Phosphatidylserine ComplexSharp-PS®||500 Mg||N/A*|
* Daily Value not established.
Other Ingredients: Gelatin, glycerin, polyglycitol syrup, purified water.
Sharp-PS® is a registered trademark of Enzymotec Ltd.
Suggested Use: Take three (3) soft gels a day for the first 4 weeks. Thereafter, a maintenance serving of one (1) soft gel a day is typically recommended, or use as directed by your health care practitioner.
TruePS™ is a highly purified and stabilized phosphatidylserine (PS) that supports brain health.†
- Keep out of reach of children
- Do not use if seal is broken or missing
- Store in a cool dry place
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- BPA Free
- Assembled in the USA
Manufactured for and Distributed by: NatureCity®
Boca Raton, FL 33487 www.naturecity.com
To re-order call toll free 1-800-593-2563
Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. Journal of Clinical Interventions in Aging. 2013;8:557-63.
Richter Y, Herzog Y, Eyal I, Cohen T. J Diet Suppl 2011 Jun; 8(2):158-68.
Richter Y, Herzog Y, Cohen T, Steinhart Y. Journal of Clinical Interventions in Aging. 2010; 5: 313–316.
Vaisman N. Phosphatidylserine may improve cognitive abilities in elderly with memory complaints: an open label trial – In preparation.
Hirayama S, Terasawa K, Rabeler R, Hirayama T, Inoue T, Tatsumi Y, Purpura M, Jäger R Journal of Human Nutrition and Dietetics. 2014 Apr;27 Suppl 2:284-91.
Yong T, Qianyong Z, Mantian M, Gang H, Jing W. Chongqing Medicine. 2011; 30:3022-23 3026.
Parker AG, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, Byrd M, Oliver J, Simbo S, Rasmussen C, Greenwood M, Kreider RB. Journal of the International Society of Sports Nutrition. 2011 Oct 21;8:16.
Gindin J, Novikov M, Dedar D, Walter- Ginzburg A, Naor S, Levi S. The Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital, Rehovot, Isryongael. Unpublished report; 2009.
Schreiber, S.,0. Kampf-Sherf, M. Gorfine, D. Kelly, Y. Oppenheim, B. Lerer.. Israel Journal of Psychiatry and Related Sciences 2000 37: 302-307.
Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Journal of Clinical Biochemistry and Nutrition. 2010 Nov; 47(3): 246–255.
Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. Dementia and Geriatric Cognitive Disorders. 2010;29(5):467-74.
Starks M, Starks S, Kingsley M, Purpura M, Jäger R. 2008 Jul 28;5:11.
Baumeister J, Barthel T, Geiss KR, Weiss M. Nutritional Neuroscience. 2008 Jun;11(3):103-10.
Jäger R, Purpura M, Geiss K, Weiss M, Baumeister J, Amatulli F, Schröder L, Herwegen H. Journal of the International Society of Sports Nutrition. 2007 Dec; 4:23.
Jorissen, B.L., F. Brouns, M.P.J. van Boxtel, R.W.H.M. Ponds. F.R.J. Verhey, J. Joiles, W.J. Riedel. Nutritional Neuroscience 2001.4: 121-134.
Crook, T. H. Vol 11, edited by R.M. Klatz, Health Quest Publications, 1998.Chicago, pp. 20-29.
Heiss, W.-D., J. Kessler, R. Mielke, B. Szelies, K. Herholz. Dementia 1994. 5: 88-98.
Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Aging (Milano). 1993 Apr;5(2):123-33.
Crook T, Petrie W, Wells C, Massari DC. Psychopharmacology Bulletin. 1992;28(1):61-6.
Engel, R.R., W. Satzger,W. Gunther,N. Kathmann,D. Bove, S.Gerke, U.Munch, H. Hippius. European Neuropsychopharmacol 1992.2:149-1 55.
Crook T, Tinklenberg J, Yesavage J, Petrie W, Nunzi M, Massari D. Neurology. May 1991 vol. 41 no. 5 644-649.
Klinkhammer P. Szelies B. Heiss W. Dementia and Geriatric Cognitive Disorders. 1990;1:197–201.
Puca, F.M., M.A. Bavarese, M.G. Minervini. Clinical Trials Journal 1987. 24: 94- 98.
Maggioni, M., G.B. Picotti, G.P. Bondiolotti, A. Panerai, T. Cenacchi, P. Nobile, F. Brambilla. Acta Psychiatrica Scandinavica 1990. 8 1 : 265-270.
Rabboni, M., F.S. Maggioni, A. Giannelli, L. Beinat. Clinical Trials Journal 1990. 27: 230-240.
Hershkowitz, M., M. Fisher, D. Bobrov, M. Rabinowitz. N.G. Bazan, L.A. Horrocks, G. Toffano (eds). Liviana Press, Padova; 1989. pp. 279-288.
Amaducci, L. and the SMID group. Psychopharmacol Bulletin 1988.24: 130-134.
Allegro, L., V. Favaretto, G. Ziliotto. Clinical Trials Journal 1987.24: 104-108.
Granata, Q., J. Di Michele. Clinical Trials Journal 1987. 24: 99-103.
Caffarra, P., V. Santamaria. Clinical Trials Journal 1987.24: 109 - 114.
Sinforiani, E., C. Agostinis, P. Merlo, S. Gualtieri, M. Mauri, A. Mancuso. Clinical Trials Journal.1987. 24: 115-124.
Palmieri, G., R. Palmieri, M.R. Inzoll, A.M. Agrati, A Vargiu. Clinica Trials Journal 1987. 24: 73-83.
Villardita, J.C., S. Grioli, G. Salmeri, F. Nicoletti, G. Pennisi. Clinical Trials Journal 1987. 24: 84-93.
Delwaide, P.J., A.M.Gyselynck-Mamboug, A. Hurlet, M. Ylieff. Acta Neurologrca Scandinavica 1986. 73: 136-140.
*The views and opinions expressed by contributors and or product reviews are their own and not
necessarily those of NatureCity. These reviews should not be taken as recommendations but rather
client opinions of the products that they have used.